Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The LB101 study in participants with advanced solid tumors (Phase 1/2) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• LB101

Snippet

Sponsor: Centessa Pharmaceuticals (UK) Limited | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED